Strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery

Expert Opinion on Drug Delivery

Volumn 13, Issue 5, 2016, Pages 609-612

  Wu, Xiao Yu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

co delivery of synergistic drug combination

Indexed keywords

ANTINEOPLASTIC AGENT; DEXTRAN SULFATE; LIPOSOME; NANOPARTICLE; POLOXAMER; POLYETHYLENEIMINE; POLYGLACTIN; POLYMER; POLYMER LIPID HYBRID NANOPARTICLE; UNCLASSIFIED DRUG;

CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; MACROMOLECULE; PARTICLE SIZE; PHYSICAL CHEMISTRY; REVIEW; SURFACE CHARGE; SUSTAINED DRUG RELEASE;

EID: 84962082158     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2016.1165662     Document Type: Review

References (15)

1. Wong HL, Rauth AM, Bendayan R, et al. Chemotherapy with anticancer drugs entrapped in solid lipid nanoparticles. Adv Drug Delivery Rev. 2007; 59: 491-504.
2. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000; 50: 161-177.
3. Wong HL, Bendayan R, Rauth AM, et al. Development of solid lipid nanoparticles containing ionically-complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci. 2004; 93: 1993-2008.
4. Wong HL, Rauth AM, Bendayan R, et al. A new solid lipid nanoparticle formulation increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res. 2006; 23: 1574-1585.
5. Wong HL, Bendayan R, Rauth AM, et al. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticle (PLN) formulations for combinational treatments of multidrug-resistant breast cancer. J Control Release. 2006; 116: 275-284.
6. Shuhendler AJ, Cheung R, Manias J, et al. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat. 2010; 119: 255-269.
7. Yang X-Z, Dou S, Wang Y-C, et al. Single-step assembly of cationic lipid-polymer hybrid nanoparticles for systemic delivery of siRNA. ACS Nano. 2012; 6: 4955-4965.
8. Zhao X, Li F, Li Y, et al. Co-delivery of HIF1alpha siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Biomaterials. 2015; 46: 13-25.
9. Prasad P, Cheng J, Shuhendler AJ, et al. A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells. Drug Delivery Transl Res. 2012; 2: 95-105.
10. Prasad P, Shuhendler AJ, Cai P, et al. Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts. Cancer Lett. 2013; 334: 263-273.
11. Shuhendler AJ, Prasad P, Zhang RX, et al. Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a non-immunocompromised breast tumor model. Mol Pharm. 2014; 11: 2659-2674.
12. Zhang RX, Cai P, Zhang T, et al. Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. Nanomed-NBM. 2016; published online first Jan 7 2016. DOI: 10.1016/j.nano.2015.12.383.
13. Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008; 2: 1696-1702.
14. Li Y, Taulier N, Rauth AM, et al. Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN). Pharm Res. 2006; 23: 1877-1887.
15. Li Y, Abbaspour MR, Grootendorst PV, et al. Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology. Eur J Pharm Biopharm. 2015; 94: 170-179.